Chronic Lymphocytic Leukaemia

ADMIRE

Does the Addition of Mitoxantrone Improve Response to FCR chemotherapy in patients with CLL: A randomised Phase II Trial of fludarabine, cyclophosphamide and rituximab (FCR) with or without mitoxantrone (M) in previously untreated chronic lymphocytic leukaemia

Familial CLL

 Genetic study of B-cell chronic lymphocytic leukaemia and other lymphoproliferative disease.

CLL Lenalidomide Maintanence 002 - The Continuum Trial

A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID®) AS MAINTENANCE THERAPY FOR PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA FOLLOWING SECOND-LINE THERAPY (The Continuum Trial)

GSK OMB 110911

A Phase III, Open Label, Randomized, Multicenter Trial of Ofatumumab Added to Chlorambucil Versus Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukaemia

Primary Outcome Measures:
•Progression-free-survival (PFS)

Secondary Outcome Measures:
•Overall response rate
•Overall survival
•Clinical benefit, safety, tolerability, changes in patient reported outcome measures and pharmacokinetics

ARCTIC

Attenuated dose Rituximab with ChemoTherapy In CLL: A randomised, phase IIB trial in previously untreated patients with Chronic Lymphocytic Leukaemia (CLL) to compare fludarabine, cyclophosphamide and rituximab (FCR) with FC, mitoxantrone and low dose rituximab (FCM-miniR)

Celgene 009

 A Phase 2, Multi-Center, Randomized, Double-Blind, Parallel-Group Study Of The Safety And Efficacy Of Different Lenalidomide (Revlimid®) Dose Regimens In Subjects With Relapsed Or Refractory B-Cell Chronic Lymphocytic Leukemia.

PiCLLe

CHOP-OR

Phase II single-arm NCRI feasibility study of CHOP in combination with ofatumumab in induction and maintenance of patients with newly diagnosed Richter's Syndrome.